capacura invests in TimeTeller

capacura invests in the Hamburg-based health tech start-up TimeTeller, thereby setting an example for progress in personalized medicine. The company's technology uses the individual circadian rhythm to determine the optimal time of day for medical treatments. According to the company, this is relevant for chemotherapy or sleep medicine, for example.

The diagnostic procedure is based on a simple saliva test, is patented, clinically validated and can be easily integrated into everyday life. TimeTeller aims to finally anchor the circadian rhythm, i.e. the human internal clock, in practical medicine.

Therapy timing rethought

Chronomedicine investigates how biological rhythms influence the success of treatment. Although this knowledge has been scientifically proven for decades, it has so far remained largely unused in everyday clinical practice. This was mainly due to a lack of practical tools.

This is where TimeTeller comes in: With its solution, an individual time profile can be created for the first time and used to optimize therapy. The aim is to achieve greater effectiveness and fewer side effects, particularly in oncology, but also in areas such as neurodegeneration (e.g. Parkinson's), women's health and sports medicine.

First mover in an emerging market

TimeTeller works with strong partners such as Charité, Techniker Krankenkasse, MSH Medical School Hamburg and Ascenion. The start-up is also well positioned in regulatory terms. Studies are underway and the first patents have been applied for. The market and technology situation gives the company clear advantages as a first mover.

capacura supports TimeTeller not only with capital, but also strategically.

The founding team brings science and strategy together

• Prof. Dr. Angela Relógio, CEO & Co-Founder, is a leading researcher in the field of chronobiology with positions at EMBL, Charité and MSH.
• Dr. Benjamin Dose, COO & Co-Founder, brings years of experience in life science consulting and is responsible for strategy, scaling and regulatory affairs.

Impact meets innovation

Since 2018, Cologne-based VC capacura has been investing specifically in start-ups that combine social impact with commercial success. We recently reported on the investments in Studyfriends and the upcycling start-up Moot. These include the areas of health, education and sustainability. With its investment in TimeTeller, capacura aims to make a significant contribution to chronomedicine and the future of personalized therapy.